Feedback
Settings

Settings

Goto Application

1. WO2013056670 - SMALL INTERFERENCE RNAS, USES THEREOF AND METHOD FOR INHIBITING THE EXPRESSION OF PLK1 GENE

PermaLink
Publication Number WO/2013/056670
Publication Date 25.04.2013
International Application No. PCT/CN2012/083195
International Filing Date 19.10.2012
Chapter 2 Demand Filed 16.08.2013
IPC
C12N 15/113 2010.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/713
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
713Double-stranded nucleic acids or oligonucleotides
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C12N 15/1135
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
1135against oncogenes or tumor suppressor genes
C12N 15/1137
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
1137against enzymes
C12N 2310/14
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
10Type of nucleic acid
14interfering N.A.
C12N 2310/141
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
10Type of nucleic acid
14interfering N.A.
141MicroRNAs, miRNAs
Applicants
  • 苏州瑞博生物技术有限公司 SUZHOU RIBO LIFE SCIENCE CO., LTD [CN]/[CN]
Inventors
  • 张鸿雁 ZHANG, Hongyan
  • 高山 GAO, Shan
Agents
  • 北京润平知识产权代理有限公司 RUNPING & PARTNERS
Priority Data
201110319067.819.10.2011CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) SMALL INTERFERENCE RNAS, USES THEREOF AND METHOD FOR INHIBITING THE EXPRESSION OF PLK1 GENE
(FR) PETITS ARN D'INTERFÉRENCE, LEURS UTILISATIONS ET PROCÉDÉ DESTINÉ À L'INHIBITION DE L'EXPRESSION DU GÈNE PLK1
(ZH) 小干扰RNA及其应用和抑制plk1基因表达的方法
front page image
Abstract
(EN) The present invention provides siRNAs for inhibiting the expression of plk1 gene, and the method for inhibiting the expression of plk1 gene in mammalian cells. The siRNAs of the prevent invention have the double-stranded structure, and said double-stranded structure is composed of the first single strand and the second single strand that are fully complementary, wherein the sequence of said first single strand is the same as the target sequence within the sequence as shown in SEQ ID NO:1, and the sequence of said second single strand is complementary to the target sequence within the sequence as shown in SEQ ID NO:1. The siRNAs of the present invention can sequence specifically mediate the inhibition of plk1 gene expression, and have a good serum stability. By the introduction of the siRNAs of the present invention into the tumor cells, the expression of plk1 gene can be effectively inhibited, and the growth of tumor cells is inhibited and the apoptosis of tumor cells is promoted.
(FR) La présente invention concerne des ARNsi destinés à l'inhibition de l'expression du gène PLK1 et un procédé destiné à l'inhibition de l'expression du gène PLK1 dans des cellules mammifères. Les ARNsi de la présente invention présentent une structure double brin et ladite structure double brin est composée du premier simple brin et du deuxième simple brin qui sont entièrement complémentaires, la séquence dudit premier simple brin étant identique à la séquence cible dans la séquence telle que montrée dans la séquence SEQ ID NO:1 et la séquence dudit deuxième simple brin étant complémentaire à la séquence cible dans la séquence telle que montrée dans la séquence SEQ ID NO:1. Les ARNsi de la présente invention peuvent, de manière spécifique à la séquence, induire l'inhibition de l'expression du gène PLK1 et présentent une bonne stabilité sérique. Par l'introduction des ARNsi de la présente invention dans les cellules tumorales, l'expression du gène PLK1 peut être inhibée efficacement, et la croissance des cellules tumorales est inhibée et l'apoptose des cellules tumorales est favorisée.
(ZH) 本发明提供抑制plk1基因表达的siRNA，及抑制哺乳动物细胞内plk1基因表达的方法。本发明的siRNA具有双链结构，所述双链结构由完全互补的第一单链和第二单链组成，其中，所述第一单链的序列与由 SEQ ID NO:1表示的序列中的靶位点序列相同，所述第二单链的序列与由 SEQ ID NO:1表示的序列中的靶位点序列互补。本发明的 siRNA能够序列特异性地介导plk1基因表达的抑制，并具有很好的血清稳定性。通过将本发明的siRNA导入至肿瘤细胞内，可以有效地抑制plk1基因的表达，并抑制肿瘤细胞生长、促进肿瘤细胞凋亡。
Related patent documents
CN104024413
US20140350079
CN106467915
US20160289687
Latest bibliographic data on file with the International Bureau
# -